REFERENCES
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21.
4. Ren B, Liu X, Suriawinata AA. Pancreatic ductal adenocarcinoma and its precursor lesions. Am J Pathol 2019;189:9-21.
5. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
6. Weniger M, Honselmann KC, Liss AS. The extracellular matrix and pancreatic cancer: a complex relationship. Cancers (Basel) 2018;10:316.
7. Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. IJMS 2017;18:1338.
10. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005;5:459-67.
11. Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 2007;6:4025-31.
12. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer 2009;125:639-48.
13. Cappello P, Principe M, Novelli F. Pancreatic cancer vaccine: a unique potential therapy. Gastrointestinal Cancer Targets Ther 2016;6:1-11.
14. Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, et al. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011;10:105-12.
15. Pandey R, Zhou M, Islam S, Chen B, Barker NK, et al. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6 ) in Pancreatic Ductal Adenocarcinoma (PDA): an integrative analysis of a novel therapeutic target. Sci Rep 2019;9:1-14.
16. Gautam SK, Kumar S, Dam V, Ghersi D, Jain M, et al. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Semin Immunol 2020;47:101391.
17. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
18. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
19. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253:328-35.
20. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-63.
21. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2:616-31.
22. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA 2004;101:13832-7.
23. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, et al. A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase i studies of safety and immune induction. Clin Cancer Res 2012;18:858-68.
24. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015;33:1325-33.
25. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clin Cancer Res 2019;25:5493-502.
26. Gjertsen MK, Breivik J, Saeterdal I, Thorsby E, Gaudernack G, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995;346:1399-400.
27. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996;65:450-3.
28. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.
29. Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011;128:1120-8.
30. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95:1474-82.
31. Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010;9:1007-16.
32. Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 2014;15:829-40.
33. Middleton G, Greenhalf W, Costello E, Shaw V, Cox T, et al. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Br J Cancer 2016;114:510-8.
34. Neoptolemos JP, Greenhalf W, Cox TF, Costello E, Shaw V, et al. Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial. JCO 2014;32:4121.
35. Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, et al. Immunotherapeutic benefit of α-interferon (IFN-α) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 2013;104:124-9.
36. Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, et al. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Cancer Sci 2019;110:2378-85.
37. Kubo T, Tsurita G, Hirohashi Y, Yasui H, Ota Y, et al. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series. Cancer Sci 2019;110:2386-95.
38. Osborne N, Sundseth R, Burks J, Cao H, Liu X, et al. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunol Immunother 2019;68:1635-48.
39. Kajihara M, Takakura K, Kanai T, Ito Z, Matsumoto Y, et al. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. World J Gastroenterol 2016;22:4446-58.
40. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, et al. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 2000;165:3451-60.
41. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6:955-64.
42. Rong Y, Qin X, Jin D, Lou W, Wu L, et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med 2012;12:173-80.
43. Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother 2014;63:797-806.
44. Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci 2015;106:397-406.
45. Koido S, Homma S, Okamoto M, Takakura K, Mori M, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res 2014;20:4228-39.
46. Takakura K, Koido S, Kan S, Yoshida K, Mori M, et al. Prognostic markers for patient outcome following vaccination with multiple MHC class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer. Anticancer Res 2015;35:555-62.
47. Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 2017;10:82.
48. Hobernik D, Bros M. DNA vaccines - how far from clinical use? International J Mol Sci 2018;19:3605.
49. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. PNAS 1994;91:9519-23.
50. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
51. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004;11:711-21.
52. Cappello P, Curcio C, Mandili G, Roux C, Bulfamante S, et al. Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners. Cancers 2018;10:51.
53. Capello M, Ferri-Borgogno S, Cappello P, Novelli F. α-enolase: a promising therapeutic and diagnostic tumor target. FEBS J 2011;278:1064-74.
54. Cappello P, Principe M, Bulfamante S, Novelli F. Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Front Biosci (Landmark Ed) 2017;22:944-59.
55. Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology 2013;144:1098-106.
56. Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res 2018;2018:1-9.
57. Chen F, Zou Z, Du J, Su S, Shao J, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest 2019;129:2056-70.
58. Batista I, Melo S. Exosomes and the future of immunotherapy in pancreatic cancer. IJMS 2019;20:567.
59. Xiao L, Erb U, Zhao K, Hackert T, Zöller M. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology 2017;6:e1319044.
60. Lu S, Zhang Z, Du P, Chard LS, Yan W, et al. A virus-infected, reprogrammed somatic cell-derived tumor cell (VIReST) vaccination regime can prevent initiation and progression of pancreatic cancer. Clin Cancer Res 2020;26:465-76.
61. Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Semin Immunopathol 2019;41:49-58.
62. Visioni A, Skitzki J. Technical considerations for the generation of adoptively transferred T cells in cancer immunotherapy. Cancers (Basel) 2016;8:86.
63. Wickström S, Lövgren T. Expansion of tumor-infiltrating lymphocytes from melanoma tumors. Methods Mol Biol 2019;1913:105-18.
64. Meng Q, Liu Z, Rangelova E, Poiret T, Ambati A, et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer. J Immunother 2016;39:81-9.
65. Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 2014;20:141-4.
66. Wang LX, Shu S, Disis ML, Plautz GE. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 2007;109:4865-76.
67. Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MWL, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood 2005;106:2995-3003.
68. Kennedy R, Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol 2006;177:2862-72.
69. Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev 2014;257:264-76.
70. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, et al. A human memory T-cell subset with stem cell-like properties. Nat Med 2011;17:1290-7.
71. Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer 2016;4:61.
72. McCarty TM, Liu X, Sun JY, Peralta EA, Diamond DJ, et al. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998;58:2601-5.
73. Zhou JH, Zhang HM, Chen Q, Han DD, Pei F, et al. Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma. World J Gastroenterol 2003;9:1808-14.
74. Hassanin H, Serba S, Schmidt J, Märten A. Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma. Clin Exp Immunol 2009;158:125-32.
75. Matsui H, Hazama S, Sakamoto K, Shindo Y, Kanekiyo S, et al. Postoperative adjuvant therapy for resectable pancreatic cancer with gemcitabine and adoptive immunotherapy. Pancreas 2017;46:994-1002.
76. Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep 2008;20:155-63.
77. Chung MJ, Park JY, Bang S, Park SW, Song SY. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother 2014;63:939-46.
78. Wang M, Shi S, Qi J, Tang X, Tian J. S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 2013;30:747.
79. D’Ippolito E, Schober K, Nauerth M, Busch DH. T cell engineering for adoptive T cell therapy: safety and receptor avidity. Cancer Immunol Immunother 2019;68:1701-12.
80. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-800.
81. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, et al. Brief communication: efficacy of adoptive cell transfer of tumor infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 2012;35:615-20.
82. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
83. Lauss M, Donia M, Harbst K, Andersen R, Mitra S, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun 2017;8:1-11.
84. Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 2019;10:128.
85. Dufait I, Liechtenstein T, Lanna A, Bricogne C, Laranga R, et al. Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica (Cairo) 2012;2012.
86. Kebriaei P, Izsvák Z, Narayanavari SA, Singh H, Ivics Z. Gene therapy with the sleeping beauty transposon system. Trends Genet 2017;33:852-70.
87. da Cunha JPC, Galante PAF, de Souza JE, de Souza RF, Carvalho PM, et al. Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci U S A 2009;106:16752-7.
88. Cohen CJ, Denkberg G, Segal D, Reiter Y. Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules. Methods Mol Biol 2003;207:269-82.
89. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014;257:83-90.
90. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol 2014;5:254.
91. FDA. Research C for BE and KYMRIAH (tisagenlecleucel). Available from: http://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel [Last accessed on 15 Apr 2020].
92. FDA. Research C for BE and YESCARTA (axicabtagene ciloleucel). Available from: http://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel [Last accessed on 15 Apr 2020].
93. European Medicines Agency. First two CAR-T cell medicines recommended for approval in the European Union. Available from: https://www.ema.europa.eu/en/news/first-two-car-t-cell-medicines-recommended-approval-european-union [Last accessed on 15 Apr 2020].
94. Hanahan D, Coussens LM. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell 2012;21:309-22.
95. Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, Witt K, Lladser A, et al. Coexpressed catalase protects chimeric antigen receptor–redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J Immunol 2016;196:759-66.
96. Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep 2017;7:39833.
97. Suarez ER, Chang DK, Sun J, Sui J, Freeman GJ, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 2016;7:34341-55.
98. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 2018;36:847-56.
99. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
100. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
101. DeSelm CJ, Tano ZE, Varghese AM, Adusumilli PS. CAR T-cell therapy for pancreatic cancer. J Surg Oncol 2017;116:63-74.
102. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014;74:2907-12.
103. Shimizu A, Hirono S, Tani M, Kawai M, Okada KI, et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 2012;103:739-46.
104. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012;18:2478-89.
105. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer 2011;10:106.
106. Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 2013;3:1870.
107. Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 2016;6:133-46.
108. Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen H, et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 2015;28:638-52.
109. Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 2018;155:29-32.
110. Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 2018;4:418-28.
112. Ishiwata T, Matsuda Y, Yoshimura H, Sasaki N, Ishiwata S, et al. Pancreatic cancer stem cells: features and detection methods. Pathol Oncol Res 2018;24:797-805.
113. Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012;143:1375-84.e5.
114. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
115. Raj D, Yang MH, Rodgers D, Hampton EN, Begum J, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut 2019;68:1052-64.
116. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-81.
117. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
118. Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012;143:1095-107.e2.
119. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DAN, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
120. Jewett A, Kos J, Fong Y, Ko MW, Safaei T, et al. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis. Semin Cancer Biol 2018;53:178-88.
121. Chi X, Yang P, Zhang E, Gu J, Xu H, et al. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Cancer Med 2019;8:4753-65.
122. Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 2017;21:3205-19.
123. Zhang E, Yang P, Gu J, Wu H, Chi X, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol 2018;11:102.
124. Taylor-Papadimitriou J, Burchell JM, Graham R, Beatson R. Latest developments in MUC1 immunotherapy. Biochem Soc Trans 2018;46:659-68.
125. Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, et al. Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 2016;44:1444-54.
126. Levi E, Klimstra DS, Adsay NV, Andea A, Basturk O. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004;57:456-62.
127. Yazdanifar M, Zhou R, Grover P, Williams C, Bose M, et al. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells 2019;8:1070.
128. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014;25:1003-12.
129. Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 2017;25:249-58.
130. Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, et al. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers (Basel) 2017;9:139.
131. Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell 2019;35:221-37.e8.
132. Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, et al. Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells. Mol Ther 2017;25:259-73.
133. Masu T, Atsukawa M, Nakatsuka K, Shimizu M, Miura D, et al. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS One 2018;13:e0200664.
134. Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, et al. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74.
135. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, et al. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999;5:2261-70.
136. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996;183:159-67.
137. Weiss JM, Gregory Alvord W, Quiñones OA, Stauffer JK, Wiltrout RH. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival. Hum Immunol 2014;75:614-20.
138. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-6.
139. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53.
140. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7.
141. Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther 2017;17:175-86.
142. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775-84.
143. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 2003;170:2727-33.
144. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, et al. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005;174:6013-22.
145. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 1991;251:70-2.
146. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
147. Mathieu M, Cotta-Grand N, Daudelin JF, Boulet S, Lapointe R, et al. CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells. Plos One 2012;7:e30139.
148. Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol 2007;65:479-86.
149. Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer ARL, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 2015;3:399-411.
150. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
151. Nowak AK, Robinson BWS, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-6.
152. Byrne KT, Vonderheide RH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep 2016;15:2719-32.
153. Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, et al. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 2015;149:201-10.
154. Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 2013;62:949-54.
155. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013;19:6286-95.
156. Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 2014;63:1769-81.
157. Quaranta V, Schmid MC. Macrophage-mediated subversion of anti-tumour immunity. Cells 2019;8:747.
158. Lenzo JC, Turner AL, Cook AD, Vlahos R, Anderson GP, et al. Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol Cell Biol 2012;90:429-40.
159. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846-59.
160. Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, et al. Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer. Cancer Res 2018;78:4253-69.
161. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057-69.
162. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013;73:1128-41.
163. Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, et al. CD86 and CD80 Differentially modulate the suppressive function of human regulatory T Cells. J Immunol 2004;172:2778-84.
164. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
165. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-45.
166. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015;15:457-72.
167. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
168. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24:541-50.
169. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-27.
170. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013;108:914-23.
171. Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 2013;62:1249-60.
172. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004;28:e26-31.
173. Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, et al. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget 2016;7:71198-210.
174. Rahn S, Krüger S, Mennrich R, Goebel L, Wesch D, et al. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Oncotarget 2019;10:1572-88.
175. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
176. Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol Immunother 2017;66:1609-17.
177. Royal RE, Levy C, Turner K, Mathur A, Hughes M, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33:828-33.
178. Looi CK, Chung FFL, Leong CO, Wong SF, Rosli R, et al. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res 2019;38:162.
179. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-7.
180. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
181. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-13.
182. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, et al. Hypermutation in pancreatic cancer. Gastroenterology 2017;152:68-74.e2.
183. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21:687-92.
184. Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front Immunol 2018;9:1878.
185. Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer 2018;118:312-24.
186. Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev 2019;78:17-30.
187. Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol 2014;25:1750-5.
188. Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist 2019; doi: 10.1634/theoncologist.2019-0473.
189. Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs 2018;36:96-102.
190. Wainberg ZA, Hochster HS, Kim EJH, George B, Kalyan A, et al. Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC). JCO 2019;37:298.
191. Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin Radiat Oncol 2013;23:273-80.
192. Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2016;2:286-94.
193. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 2017;14:365-79.
194. Azad A, Yin Lim S, D’Costa Z, Jones K, Diana A, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 2017;9:167-80.
195. Victor CTS, Rech AJ, Maity A, Rengan R, Pauken KE, et al. Radiation and dual checkpoint blockade activates non-redundant immune mechanisms in cancer. Nature 2015;520:373-7.
196. Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, et al. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer. Cancer Res 2018;78:4282-91.
197. Guo S, Contratto M, Miller G, Leichman L, Wu J. Immunotherapy in pancreatic cancer: unleash its potential through novel combinations. World J Clin Oncol 2017;8:230-40.
198. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, et al. Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36:382-9.
199. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J Immunother 2015;38:1-11.
200. Lutz ER, Kinkead H, Jaffee EM, Zheng L. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology 2014:3e962401.
201. Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: where are we now? World J Gastroenterol 2018;24:2137-51.
202. Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989;81:1709-17.
203. Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, et al. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model. J Immunol 2010;185:2580-8.
204. Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 2013;122:1399-410.
205. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016;34:4102-9.
206. Iafolla MAJ, Juergens RA. Update on programmed death-1 and programmed death-ligand 1 inhibition in the treatment of advanced or metastatic non-small cell lung cancer. Front Oncol 2017;7:67.
207. Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, et al. PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-hodgkin lymphoma. Front Immunol 2018;9:1955.
208. John LB, Devaud C, Duong CPM, Yong CS, Beavis PA, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013;19:5636-46.
209. Blair AB, Zheng L. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. Chin Clin Oncol 2017;6:31.
210. Hu B, Zou Y, Zhang L, Tang J, Niedermann G, et al. Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Human Gene Therapy 2018;30:446-58.
211. Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, et al. CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Rep 2018;23:1448-60.
212. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016;37:208-20.
213. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013;32:1743-51.
214. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65.
215. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can treg cells be a new therapeutic target? Cancer Sci 2019;110:2080-9.
216. Pandha H, Rigg A, John J, Lemoine N. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol 2007;148:127-35.
217. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007;67:5479-88.
218. Fogar P, Basso D, Fadi E, Greco E, Pantano G, et al. Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle. Pancreas 2011;40:1131-7.
219. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-12.
220. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52.
